MS

Mark Sullivan

Chief Legal Officer and Corporate Secretary

Definium Therapeutics

Therapeutic Areas

Definium Therapeutics Pipeline

DrugIndicationPhase
DT120Major Depressive Disorder (MDD)Phase 3
DT402Autism Spectrum Disorder (ASD)Phase 2a